GlassScriptPhysician profile
Mark J Rubin
NPI 1376538496
$1,924.54
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $359 · 2021: $323 · 2022: $148 · 2023: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $271.95 | 2019-2023 | Senza |
| Collegium Pharmaceutical, INC. | $270.83 | 2019-2023 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.93 | 2019-2023 | Relistor |
| Biodelivery Sciences International, INC. | $150.31 | 2019-2021 | |
| Almatica Pharma LLC | $134.13 | 2020-2023 | Gralise |
| Boston Scientific Corporation | $131.32 | 2019 | |
| Sunovion Pharmaceuticals INC. | $108.87 | 2019 | |
| Genentech, INC. | $100.90 | 2019 | |
| Alnylam Pharmaceuticals INC. | $67.46 | 2023 | Givlaari |
| Pfizer INC. | $52.52 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $50.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $41.75 | 2019-2020 | |
| Alevio, LLC | $38.88 | 2023 | Sicure Sacroiliac Joint Fusion System |
| Medtronic USA, INC. | $33.75 | 2019-2020 | |
| Spr Therapeutics, INC | $33.71 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $33.10 | 2019 | |
| Saluda Medical Americas, INC. | $28.10 | 2023 | Evoke Scs |
| Ibsa Pharma INC. | $27.34 | 2021 | |
| Nalu Medical, INC. | $27.17 | 2021 | |
| Redhill Biopharma INC. | $26.54 | 2020-2021 | |
| Abbvie INC. | $23.35 | 2022 | |
| Vertical Pharmaceuticals, LLC | $20.97 | 2019 | |
| Averitas Pharma INC. | $18.94 | 2023 | Qutenza |
| Ultragenyx Pharmaceutical INC. | $18.76 | 2021 | |
| Spinal Simplicity, LLC | $18.21 | 2022 | |
| Neos Therapeutics, LP | $15.30 | 2020 | |
| Daiichi Sankyo INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.